{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Polyangéite microscopique : Questions médicales les plus fréquentes",
"headline": "Polyangéite microscopique : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Polyangéite microscopique : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-07-03",
"dateModified": "2025-03-30",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Polyangéite microscopique"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Vascularites associées aux anticorps anti-cytoplasme des neutrophiles",
"url": "https://questionsmedicales.fr/mesh/D056648",
"about": {
"@type": "MedicalCondition",
"name": "Vascularites associées aux anticorps anti-cytoplasme des neutrophiles",
"code": {
"@type": "MedicalCode",
"code": "D056648",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "C20.111.193"
}
}
},
"about": {
"@type": "MedicalCondition",
"name": "Polyangéite microscopique",
"alternateName": "Microscopic Polyangiitis",
"code": {
"@type": "MedicalCode",
"code": "D055953",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Jason Jungsik Song",
"url": "https://questionsmedicales.fr/author/Jason%20Jungsik%20Song",
"affiliation": {
"@type": "Organization",
"name": "Division of Rheumatology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, and Institute for Immunology and Immunological Diseases, Yonsei University College of Medicine, Seoul, Republic of Korea."
}
},
{
"@type": "Person",
"name": "Sang-Won Lee",
"url": "https://questionsmedicales.fr/author/Sang-Won%20Lee",
"affiliation": {
"@type": "Organization",
"name": "Division of Rheumatology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, and Institute for Immunology and Immunological Diseases, Yonsei University College of Medicine, Seoul, Republic of Korea. sangwonlee@yuhs.ac."
}
},
{
"@type": "Person",
"name": "Sung Soo Ahn",
"url": "https://questionsmedicales.fr/author/Sung%20Soo%20Ahn",
"affiliation": {
"@type": "Organization",
"name": "Division of Rheumatology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Republic of Korea."
}
},
{
"@type": "Person",
"name": "Yong-Beom Park",
"url": "https://questionsmedicales.fr/author/Yong-Beom%20Park",
"affiliation": {
"@type": "Organization",
"name": "Division of Rheumatology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, and Institute for Immunology and Immunological Diseases, Yonsei University College of Medicine, Seoul, Republic of Korea."
}
},
{
"@type": "Person",
"name": "Taejun Yoon",
"url": "https://questionsmedicales.fr/author/Taejun%20Yoon",
"affiliation": {
"@type": "Organization",
"name": "Department of Medical Science, College of Medicine, BK21 Plus Project, Yonsei University, Seoul, Republic of Korea."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Circulating Immune Complexes and Complement Activation in Sensitized Kidney Transplant Recipients.",
"datePublished": "2024-10-10",
"url": "https://questionsmedicales.fr/article/39456685",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.3390/ijms252010904"
}
},
{
"@type": "ScholarlyArticle",
"name": "Tear fluid and complement activation products in tears after ocular surgery.",
"datePublished": "2023-07-18",
"url": "https://questionsmedicales.fr/article/37464366",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1186/s12886-023-03037-6"
}
},
{
"@type": "ScholarlyArticle",
"name": "Complement activation profiles in anti-acetylcholine receptor positive myasthenia gravis.",
"datePublished": "2023-02-24",
"url": "https://questionsmedicales.fr/article/36752022",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1111/ene.15730"
}
},
{
"@type": "ScholarlyArticle",
"name": "Zilucoplan, a macrocyclic peptide inhibitor of human complement component 5, uses a dual mode of action to prevent terminal complement pathway activation.",
"datePublished": "2023-08-09",
"url": "https://questionsmedicales.fr/article/37622108",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.3389/fimmu.2023.1213920"
}
},
{
"@type": "ScholarlyArticle",
"name": "What complements complement in transplant-associated thrombotic microangiopathy?",
"datePublished": "2022-08-09",
"url": "https://questionsmedicales.fr/article/35942659",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1111/bjh.18402"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Maladies du système immunitaire",
"item": "https://questionsmedicales.fr/mesh/D007154"
},
{
"@type": "ListItem",
"position": 3,
"name": "Maladies auto-immunes",
"item": "https://questionsmedicales.fr/mesh/D001327"
},
{
"@type": "ListItem",
"position": 4,
"name": "Vascularites associées aux anticorps anti-cytoplasme des neutrophiles",
"item": "https://questionsmedicales.fr/mesh/D056648"
},
{
"@type": "ListItem",
"position": 5,
"name": "Polyangéite microscopique",
"item": "https://questionsmedicales.fr/mesh/D055953"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Polyangéite microscopique - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Polyangéite microscopique",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-14",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Polyangéite microscopique",
"description": "Comment diagnostiquer la polyangéite microscopique ?\nQuels tests sanguins sont utilisés ?\nQuels symptômes orientent vers ce diagnostic ?\nLa biopsie est-elle toujours nécessaire ?\nQuels examens d'imagerie sont recommandés ?",
"url": "https://questionsmedicales.fr/mesh/D055953?mesh_terms=Complement+Activation&page=3#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Polyangéite microscopique",
"description": "Quels sont les symptômes courants ?\nLa polyangéite microscopique cause-t-elle des problèmes rénaux ?\nY a-t-il des symptômes respiratoires associés ?\nLes symptômes varient-ils d'un patient à l'autre ?\nPeut-on avoir des symptômes neurologiques ?",
"url": "https://questionsmedicales.fr/mesh/D055953?mesh_terms=Complement+Activation&page=3#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Polyangéite microscopique",
"description": "Peut-on prévenir la polyangéite microscopique ?\nQuels conseils de mode de vie peuvent aider ?\nLes vaccinations sont-elles recommandées ?\nFaut-il éviter certains médicaments ?\nLe suivi médical est-il important ?",
"url": "https://questionsmedicales.fr/mesh/D055953?mesh_terms=Complement+Activation&page=3#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Polyangéite microscopique",
"description": "Quels traitements sont utilisés pour cette maladie ?\nLes corticostéroïdes sont-ils efficaces ?\nCombien de temps dure le traitement ?\nY a-t-il des effets secondaires aux traitements ?\nDes traitements biologiques sont-ils disponibles ?",
"url": "https://questionsmedicales.fr/mesh/D055953?mesh_terms=Complement+Activation&page=3#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Polyangéite microscopique",
"description": "Quelles sont les complications possibles ?\nLa polyangéite microscopique peut-elle être mortelle ?\nComment prévenir les complications ?\nLes complications affectent-elles la qualité de vie ?\nY a-t-il des complications à long terme ?",
"url": "https://questionsmedicales.fr/mesh/D055953?mesh_terms=Complement+Activation&page=3#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Polyangéite microscopique",
"description": "Quels sont les facteurs de risque connus ?\nL'âge influence-t-il le risque ?\nLes infections peuvent-elles déclencher la maladie ?\nLe sexe joue-t-il un rôle dans le risque ?\nDes facteurs environnementaux sont-ils impliqués ?",
"url": "https://questionsmedicales.fr/mesh/D055953?mesh_terms=Complement+Activation&page=3#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostiquer la polyangéite microscopique ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le diagnostic repose sur des analyses sanguines, des biopsies et des examens d'imagerie."
}
},
{
"@type": "Question",
"name": "Quels tests sanguins sont utilisés ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les tests incluent la recherche d'anticorps anti-MPO et des marqueurs d'inflammation."
}
},
{
"@type": "Question",
"name": "Quels symptômes orientent vers ce diagnostic ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Symptômes comme la fatigue, la fièvre, et des douleurs articulaires peuvent indiquer la maladie."
}
},
{
"@type": "Question",
"name": "La biopsie est-elle toujours nécessaire ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Non, la biopsie n'est pas toujours nécessaire, mais elle peut confirmer le diagnostic."
}
},
{
"@type": "Question",
"name": "Quels examens d'imagerie sont recommandés ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les IRM et les scanners peuvent aider à visualiser les atteintes organiques."
}
},
{
"@type": "Question",
"name": "Quels sont les symptômes courants ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes incluent fatigue, fièvre, éruptions cutanées et douleurs musculaires."
}
},
{
"@type": "Question",
"name": "La polyangéite microscopique cause-t-elle des problèmes rénaux ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elle peut entraîner une insuffisance rénale aiguë due à l'inflammation des vaisseaux rénaux."
}
},
{
"@type": "Question",
"name": "Y a-t-il des symptômes respiratoires associés ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des symptômes comme la toux et des douleurs thoraciques peuvent survenir."
}
},
{
"@type": "Question",
"name": "Les symptômes varient-ils d'un patient à l'autre ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'intensité et la combinaison des symptômes peuvent varier considérablement."
}
},
{
"@type": "Question",
"name": "Peut-on avoir des symptômes neurologiques ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des symptômes comme des maux de tête ou des troubles de la vision peuvent apparaître."
}
},
{
"@type": "Question",
"name": "Peut-on prévenir la polyangéite microscopique ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Il n'existe pas de méthode de prévention spécifique, mais un suivi médical régulier est conseillé."
}
},
{
"@type": "Question",
"name": "Quels conseils de mode de vie peuvent aider ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Adopter un mode de vie sain, éviter le tabac et gérer le stress peuvent être bénéfiques."
}
},
{
"@type": "Question",
"name": "Les vaccinations sont-elles recommandées ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les vaccinations peuvent aider à prévenir certaines infections, surtout sous traitement immunosuppresseur."
}
},
{
"@type": "Question",
"name": "Faut-il éviter certains médicaments ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certains médicaments peuvent aggraver la maladie, il est donc important de consulter un médecin."
}
},
{
"@type": "Question",
"name": "Le suivi médical est-il important ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, un suivi régulier permet de surveiller l'évolution de la maladie et d'ajuster le traitement."
}
},
{
"@type": "Question",
"name": "Quels traitements sont utilisés pour cette maladie ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les traitements incluent des corticostéroïdes et des immunosuppresseurs pour réduire l'inflammation."
}
},
{
"@type": "Question",
"name": "Les corticostéroïdes sont-ils efficaces ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, ils sont souvent efficaces pour contrôler l'inflammation et soulager les symptômes."
}
},
{
"@type": "Question",
"name": "Combien de temps dure le traitement ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "La durée du traitement varie, mais peut durer plusieurs mois à plusieurs années."
}
},
{
"@type": "Question",
"name": "Y a-t-il des effets secondaires aux traitements ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les effets secondaires peuvent inclure des infections, des troubles digestifs et des problèmes osseux."
}
},
{
"@type": "Question",
"name": "Des traitements biologiques sont-ils disponibles ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des traitements biologiques comme le rituximab peuvent être utilisés dans certains cas."
}
},
{
"@type": "Question",
"name": "Quelles sont les complications possibles ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications incluent l'insuffisance rénale, les infections et les problèmes pulmonaires."
}
},
{
"@type": "Question",
"name": "La polyangéite microscopique peut-elle être mortelle ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, sans traitement approprié, elle peut entraîner des complications graves et potentiellement mortelles."
}
},
{
"@type": "Question",
"name": "Comment prévenir les complications ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un traitement précoce et un suivi régulier sont essentiels pour prévenir les complications."
}
},
{
"@type": "Question",
"name": "Les complications affectent-elles la qualité de vie ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les complications peuvent significativement affecter la qualité de vie des patients."
}
},
{
"@type": "Question",
"name": "Y a-t-il des complications à long terme ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des complications à long terme peuvent inclure des problèmes rénaux chroniques et des troubles pulmonaires."
}
},
{
"@type": "Question",
"name": "Quels sont les facteurs de risque connus ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les facteurs incluent des antécédents familiaux, le tabagisme et certaines infections."
}
},
{
"@type": "Question",
"name": "L'âge influence-t-il le risque ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, la polyangéite microscopique est plus fréquente chez les adultes âgés de 50 à 70 ans."
}
},
{
"@type": "Question",
"name": "Les infections peuvent-elles déclencher la maladie ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certaines infections virales ou bactériennes peuvent être des déclencheurs."
}
},
{
"@type": "Question",
"name": "Le sexe joue-t-il un rôle dans le risque ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, la maladie est légèrement plus fréquente chez les hommes que chez les femmes."
}
},
{
"@type": "Question",
"name": "Des facteurs environnementaux sont-ils impliqués ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'exposition à certains produits chimiques ou médicaments peut augmenter le risque."
}
}
]
}
]
}
Chronic antibody-mediated rejection in kidney transplantation is a common cause of graft loss in the late post-transplant period. In this process, the role of the classical complement activation pathw...
Due to technological advancements, surgical invasiveness has been reduced. However, cataract surgery has been implicated in causing postoperative inflammation, including dry eye syndrome. The innate i...
Forty-three patients (23 women; median age, 69 years) were enrolled in this prospective study and underwent phacoemulsification and vitrectomy. We measured Schirmer's test (ST) and CAPs in the tears a...
The median ST (8.5 mm) at baseline increased to 16 mm at 4 days ( P < 0.001) and 10 mm at 1 month (P = 0.44). The C3a levels (1202 pg/ml) at baseline increased to 2753 pg/ml at 4 days (P < 0.001), and...
The CAPs levels in tears increased after vitrectomy combined with cataract surgery. A preoperative deficit in tear secretion might induce prolonged complement activation and delayed recovery of ocular...
Complement component 5 (C5) targeting therapies are clinically beneficial in patients with acetylcholine receptor antibody...
In a case-control study, concentrations of C3a, C5a and sC5b9 were simultaneously quantified, indicating general activation of the complement system, whether via the classical and lectin pathways (C4a...
Treatment-naïve patients with AChR-Ab...
Markers indicative of complement activation are prominently increased in patients with AChR-Ab MG despite standard immunosuppressive therapies. Complement inhibition proximal to C5 cleavage should be ...
The complement system is a key component of the innate immune system, and its aberrant activation underlies the pathophysiology of various diseases. Zilucoplan is a macrocyclic peptide that binds and ...
The interaction of zilucoplan with C5, including for clinical C5 R885 variants, was investigated using surface plasmon resonance (SPR), hemolysis assays, and ELISA. The interference of C5b6 formation ...
Zilucoplan specifically bound human complement C5 with high affinity, competitively inhibited the binding of C5 to C3b, and blocked C5 cleavage by C5 convertases and the assembly of the cytolytic memb...
Our findings demonstrate that zilucoplan uses a dual mode of action to potently inhibit the activation of C5 and terminal complement pathway including wild-type and clinical R885 variants that do not ...
Transplant-associated thrombotic microangiopathy remains a lethal complication of haematopoietic stem cell transplant and not all patients respond to terminal complement inhibitors. Qi et al. show tha...
The intravascular formation of neutrophil extracellular traps (NETs) is a trigger for coagulation and blood vessel occlusion. NETs are released from neutrophils as a response to strong inflammatory si...
In the present study, we used different microfluidic setups in combination with fluorescence microscopy to investigate the influence of neutrophil-derived extracellular DNA fibers on blood rheology, i...
We found that extended DNA fiber networks decelerate blood flow and promote intravascular occlusion of blood vessels independent of the plasmatic coagulation. Associated with the DNA dependent occlusi...
In conclusion, we found that DNA fibers as the principal component of NETs are sufficient to induce blood aggregation even in the absence of the coagulation system. Moreover, we discovered that comple...
Hidradenitis suppurativa (HS) is a chronic auto-inflammatory skin disease with a complex and multifactorial pathogenesis involving both the innate and adaptive immune system. Despite limited evidence ...
Sepsis is characterized by a dysregulated immune response to infection. The complement system plays an important role in the host defence to pathogens. However, exaggerated complement activation might...
Secondary analysis of complement factors in a prospective study in 209 hospitalized sepsis patients, of whom the majority presented with shock. Concentrations of complement factors C3, C3a, C3c, C5, C...
The concentration of complement factors in plasma of severely ill sepsis patients indicated profound activation of the complement system (all P < 0.01 compared to healthy controls). Spearman rank corr...
Once an infection progresses to severe sepsis or septic shock, the complement pathway is already profoundly activated and is no longer related to a dysregulated inflammatory response, nor to clinical ...
Complement activation through antibody-antigen complexes is crucial in various pathophysiological processes and utilized in immunotherapies to eliminate infectious agents, regulatory immune cells, or ...
To prepare nanoscale ultrasound contrast agents (Nano-UCAs) and examine the role of their surface charge in complement activation and phagocytosis....
We analyzed serum proteins present in the corona formed on Nano-UCAs and evaluated two important protein markers of complement activation (C3 and SC5b-9). The effect of surface charge on phagocytosis ...
When Nano-UCAs were incubated with human serum, they were opsonized by various blood proteins, especially C3. Highly charged Nano-UCAs, whether positive or negative, were favorably opsonized by comple...
Charged Nano-UCAs show a higher tendency to activated complement system, and are efficiently engulfed by macrophages. The present results provide meaningful insights into the role of the surface charg...